Clinical epidemiological investigation and modern statistics will be used. Syndrome was quantified by TCM syndrome score scale. Metabonomics, proteomics, transcriptomics, enzyme-linked immunosorbent assay, xanthine oxidation method and thiobarbital method will be used to detect the relevant indicators in serum, urine and tongue coating, and "disease syndrome cell model" will be constructed to detect the relevant indicators. Objective to clarify the epigenetic basis, molecular biological regulation mechanism and core function characteristics of phgdh expression decline caused by PDR and SKYD of dyslipidemia, analyze the correlation between phgdh, serine metabolic pathway product concentration and oxidative stress level, and reveal the scientific connotation of the disease syndrome.
Clinical epidemiological investigation and modern statistics will be used. Syndrome was quantified by TCM syndrome score scale. Metabonomics, proteomics, transcriptomics, enzyme-linked immunosorbent assay, xanthine oxidation method and thiobarbital method will be used to detect the relevant indicators in serum, urine and tongue coating, and "disease syndrome cell model" will be constructed to detect the relevant indicators. Objective to clarify the epigenetic basis, molecular biological regulation mechanism and core function characteristics of phgdh expression decline caused by PDR and SKYD of dyslipidemia, analyze the correlation between phgdh, serine metabolic pathway product concentration and oxidative stress level, and reveal the scientific connotation of the disease syndrome.
Study Type
OBSERVATIONAL
Enrollment
240
cross-sectional study without intervention
Dongzhimen Hospital
Beijing, Dongcheng, China
RECRUITINGRoutine Blood Examination
PDR group, SKYD group and NC group's Routine Blood Examination
Time frame: 2 years
Blood Biochemistry
PDR group, SKYD group and NC group's Blood Biochemistry
Time frame: 2 years
Routine Urine Examination
PDR group, SKYD group and NC group's Routine Urine Examination
Time frame: 2 years
the Methylation Level of PHGDH
Methylation sensitive restriction enzyme technique combined with PCR (msre-pcr) will be used to detect the Methylation Level of PHGDH in PDR group, SKYD group and NC group.
Time frame: 2 years
the Methylation Level of PHGDH in the cell models of disease-TCM syndrome
Methylation sensitive restriction enzyme technique combined with PCR (msre-pcr) will be used to detect the Methylation Level of PHGDH in the cell models of disease-TCM syndrome.
Time frame: 2 years
Distribution of h3k4me3, H3K9Ac and h3k27ac histones in PHGDH gene promoter
The distribution of h3k4me3, H3K9Ac and h3k27ac histones in the promoter of PHGDH gene will be detected by chromatin immunoprecipitation assay (chip) in PDR group, SKYD group and NC group.
Time frame: 2 years
Distribution of h3k4me3, H3K9Ac and h3k27ac histones in PHGDH gene promoter in the cell models of disease-TCM syndrome
The distribution of h3k4me3, H3K9Ac and h3k27ac histones in the promoter of PHGDH gene will be detected by chromatin immunoprecipitation assay (chip) in the cell models of disease-TCM syndrome.
Time frame: 2 years
3-phosphoglycerate dehydrogenase (PHGDH) RNA
PHGDH RNA level will be detected by fluorescence quantitative PCR in PDR group, SKYD group and NC group.
Time frame: 2 years
3-phosphoglycerate dehydrogenase (PHGDH) RNA in the cell models of disease-TCM syndrome
PHGDH RNA level will be detected by fluorescence quantitative PCR in the cell models of disease-TCM syndrome.
Time frame: 2 years
Phosphoserine aminotransferase (PSAT1) RNA
PSAT1 RNA level will be detected by fluorescence quantitative PCR in the cell models of disease-TCM syndrome.
Time frame: 2 years
Phosphoserine aminotransferase (PSAT1) RNA in the cell models of disease-TCM syndrome
PSAT1 RNA level will be detected by fluorescence quantitative PCR in the cell models of disease-TCM syndrome.
Time frame: 2 years
Phosphoserine acid phosphatase (PSPH) RNA
PSPH RNA level will be detected by fluorescence quantitative PCR in PDR group, SKYD group and NC group.
Time frame: 2 years
Phosphoserine acid phosphatase (PSPH) RNA in the cell models of disease-TCM syndrome
PSPH RNA level will be detected by fluorescence quantitative PCR in the cell models of disease-TCM syndrome.
Time frame: 2 years
Serine
Serine levels will be measured by targeted metabonomics in PDR group, SKYD group and NC group.
Time frame: 2 years
the differences of metabonomics in the cell models of disease-TCM syndrome
The differences of metabonomics in blood, urine and tongue coating will be detected by metabonomics in the cell models of disease-TCM syndrome.
Time frame: 2 years
the differences of transcriptomics in the cell models of disease-TCM syndrome
The differences of transcriptomics in blood, urine and tongue coating will be detected by transcriptomics in the cell models of disease-TCM syndrome.
Time frame: 2 years
the differences of metabonomics
The differences of metabonomics in blood, urine and tongue coating will be detected by metabonomics in PDR group, SKYD group and NC group.
Time frame: 2 years
the differences of proteomics in the cell models of disease-TCM syndrome
The differences of proteomics in blood, urine and tongue coating will be detected by proteomics in the cell models of disease-TCM syndrome.
Time frame: 2 years
the differences of transcriptomics
The differences of transcriptomics in blood, urine and tongue coating will be detected by transcriptomics in PDR group, SKYD group and NC group.
Time frame: 2 years
the differences of proteomics
The differences of proteomics in blood, urine and tongue coating will be detected by proteomics in PDR group, SKYD group and NC group.
Time frame: 2 years
Malondialdehyde (MDA) in the cell models of disease-TCM syndrome
Determination of MDA content by thiobarbituric acid method in the cell models of disease-TCM syndrome.
Time frame: 2 years
Malondialdehyde (MDA)
Determination of MDA content by thiobarbituric acid method in PDR group, SKYD group and NC group.
Time frame: 2 years
Superoxide Dismutase (SOD) in the cell models of disease-TCM syndrome.
Determination of SOD activity by xanthine oxidase method in the cell models of disease-TCM syndrome.
Time frame: 2 years
Superoxide Dismutase (SOD)
Determination of SOD activity by xanthine oxidase method in PDR group, SKYD group and NC group.
Time frame: 2 years
Peroxynitrite anion (ONOO-) in the cell models of disease-TCM syndrome
ONOO- will be detected by ELISA in the cell models of disease-TCM syndrome.
Time frame: 2 years
Peroxynitrite anion (ONOO-)
ONOO- will be detected by ELISA in PDR group, SKYD group and NC group.
Time frame: 2 years
Nicotinamide Adenine Dinucleotide Phosphate (NADPH) the cell models of disease-TCM syndrome
NADPH will be detected by ELISA in the cell models of disease-TCM syndrome.
Time frame: 2 years
Nicotinamide Adenine Dinucleotide Phosphate (NADPH)
NADPH will be detected by ELISA in PDR group, SKYD group and NC group.
Time frame: 2 years
Glutathione (GSH) in the cell models of disease-TCM syndrome.
GSH will be detected by ELISA in the cell models of disease-TCM syndrome.
Time frame: 2 years
Glutathione (GSH)
GSH will be detected by ELISA in PDR group, SKYD group and NC group.
Time frame: 2 years
3-phosphoglycerate dehydrogenase（PHGDH） in the cell models of disease-TCM syndrome
PHGDH will be detected by ELISA in the cell models of disease-TCM syndrome.
Time frame: 2 years
3-phosphoglycerate dehydrogenase（PHGDH）
PHGDH will be detected by ELISA in PDR group, SKYD group and NC group.
Time frame: 2 years
Threonine in the cell models of disease-TCM syndrome
Threonine levels will be measured by targeted metabonomics in the cell models of disease-TCM syndrome.
Time frame: 2 years
Threonine
Threonine levels will be measured by targeted metabonomics in PDR group, SKYD group and NC group.
Time frame: 2 years
Glycine in the cell models of disease-TCM syndrome
Glycine levels will be measured by targeted metabonomics in the cell models of disease-TCM syndrome.
Time frame: 2 years
Glycine
Glycine levels will be measured by targeted metabonomics in PDR group, SKYD group and NC group.
Time frame: 2 years
The clinical TCM scores of SKYD
The minimum value is 0 and maximum value is 35, and higher scores mean a worse outcome.
Time frame: 2 years
The clinical TCM scores of PDR
The minimum value is 0 and maximum value is 44, and higher scores mean a worse outcome.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.